NCT04762225View on ClinicalTrials.gov

RPTR-168 in Patients With Human Papillomavirus Strain 16 (HPV-16) E6/E7 Positive Tumors and Melanoma

PHASE1TerminatedINTERVENTIONAL
Enrollment

7

Participants

Timeline

Start Date

May 10, 2021

Primary Completion Date

September 14, 2022

Study Completion Date

October 11, 2022

Conditions
Head and Neck Squamous Cell CarcinomaMelanomaCervical Cancer
Interventions
BIOLOGICAL

RPTR-168

Escalating doses of RPTR-168 as a monotherapy

Trial Locations (4)

28078

Carolina BioOncology Institute, Huntersville

48109

University of Michigan Comprehensive Cancer Center, Ann Arbor

85258

HonorHealth Research Institute, Scottsdale

90033

USC Norris Comprehensive Cancer Center, Los Angeles

Sponsors
All Listed Sponsors
lead

Repertoire Immune Medicines

INDUSTRY

NCT04762225 - RPTR-168 in Patients With Human Papillomavirus Strain 16 (HPV-16) E6/E7 Positive Tumors and Melanoma | Biotech Hunter | Biotech Hunter